Search

Your search keyword '"Llamas-Velasco, M"' showing total 629 results
Start Over Author "Llamas-Velasco, M"
629 results on '"Llamas-Velasco, M"'

1. [Artículo traducido] Eficacia y seguridad del risankizumab en pacientes con psoriasis en el mundo real: un estudio retrospectivo, multicéntrico y no intervencionista

Author

Martorell-Calatayud, A., Santos-Alarcón, S., Sahuquillo-Torralba, A., Rivera-Díaz, R., Belinchón-Romero, I., Ruiz-Genao, D., Romero-Maté, A., Ruiz-Villaverde, R., Ferran-Farrés, M., Gallardo-Hernández, F., Almenara-Blasco, M., Suarez-Perez, J.A., González-Cantero, Á., Martínez-Lorenzo, E., Fernández-Armenteros, J.M., del Alcázar-Viladomiu, E., García-Latasa, J., Rocamora-Durant, V., Ara-Martín, M., Mateu-Puchades, A., Llamas-Velasco, M., Vilarrasa, E., Velasco-Pastor, M., De la Cueva, P., Carrascosa, J.M., and Magdaleno-Tapial, J.

Published
2025
Full Text
View/download PDF

2. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

Author

Martorell-Calatayud, A., Santos-Alarcón, S., Sahuquillo-Torralba, A., Rivera-Díaz, R., Belinchón-Romero, I., Ruiz-Genao, D., Romero-Maté, A., Ruiz-Villaverde, R., Ferran-Farrés, M., Gallardo-Hernández, F., Almenara-Blasco, M., Suarez-Perez, J.A., González-Cantero, Á., Martínez-Lorenzo, E., Fernández-Armenteros, J.M., del Alcázar-Viladomiu, E., García-Latasa, J., Rocamora-Durant, V., Ara-Martín, M., Mateu-Puchades, A., Llamas-Velasco, M., Vilarrasa, E., Velasco-Pastor, M., De la Cueva, P., Carrascosa, J.M., and Magdaleno-Tapial, J.

Published
2025
Full Text
View/download PDF

3. [Translated article] Measurement Assessment of Minimal Disease Activity in Psoriasis in Spain: A National Cross-Sectional Study

Author

Carretero Hernández, G., Ara Martín, M., Armesto Alonso, S., Belinchón Romero, I., Eiris Salvado, N., Ferrán Farrés, M., Galache Osuna, C., García Bustínduy, M., García Latasa de Araníbar, J., Juliá Manresa, M., Llamas Velasco, M., López Ferrer, A., Roncero Riesco, M., Ruiz Genao, D., Ruíz-Villaverde, R., Salgado Boquete, L., Soria Martínez, C., Vilarrasa Rull, E., and Descalzo, M.A.

Published
2025
Full Text
View/download PDF

4. Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional

Author

Carretero Hernández, G., Ara Martín, M., Armesto Alonso, S., Belinchón Romero, I., Eiris Salvado, N., Ferrán Farrés, M., Galache Osuna, C., García Bustínduy, M., García Latasa de Araníbar, J., Juliá Manresa, M., Llamas Velasco, M., López Ferrer, A., Roncero Riesco, M., Ruiz Genao, D., Ruíz-Villaverde, R., Salgado Boquete, L., Soria Martínez, C., Vilarrasa Rull, E., and Descalzo, M.A.

Published
2025
Full Text
View/download PDF

7. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas

Author

Izu-Belloso, R., Gainza-Apraiz, I., Ortiz-Romero, P., Servitje-Bedate, O., Fernández de Misa-Cabrera, R., Peñate, Y., Hernandez-Machin, B., Estrach-Panella, T., Llamas-Velasco, M., Yanguas-Bayona, J.I., Morillo-Andujar, M., Acebo-Mariñas, E., Perez-Gala, S., Armario-Hita, J.C., Sanchez-Sambucety, P., Ortiz-Brugues, A., Eguren-Michelena, C., Bielsa-Marsol, I., Lopez-Pestaña, A., Blanes-Martinez, M., Fernandez-Guarino, M., and Lopez-Lerma, I.

Published
2024
Full Text
View/download PDF

8. [Artículo traducido] Experiencia con bexaroteno en linfoma cutáneo de células T: un estudio del Grupo Español de Linfomas Cutáneos (GELC)

Author

Izu-Belloso, R., Gainza-Apraiz, I., Ortiz-Romero, P., Servitje-Bedate, O., Fernández de Misa-Cabrera, R., Peñate, Y., Hernandez-Machin, B., Estrach-Panella, T., Llamas-Velasco, M., Yanguas-Bayona, J.I., Morillo-Andujar, M., Acebo-Mariñas, E., Perez-Gala, S., Armario-Hita, J.C., Sanchez-Sambucety, P., Ortiz-Brugues, A., Eguren-Michelena, C., Bielsa-Marsol, I., Lopez-Pestaña, A., Blanes-Martinez, M., Fernandez-Guarino, M., and Lopez-Lerma, I.

Published
2024
Full Text
View/download PDF

15. Valoración de la medida de Actividad Mínima de Enfermedad en Psoriasis en España: estudio transversal nacional

Author

Carretero Hernández, G, primary, Ara Martín, M, additional, Armesto Alonso, S, additional, Belinchón Romero, I, additional, Eiris Salvado, N, additional, Ferrán Farrés, M, additional, Galache Osuna, C, additional, García Bustínduy, M, additional, de Araníbar, J García Latasa, additional, Juliá Manresa, M, additional, Llamas Velasco, M, additional, López Ferrer, A, additional, Roncero Riesco, M, additional, Ruiz Genao, D, additional, Ruíz-Villaverde, R, additional, Salgado Boquete, L, additional, Soria Martínez, C, additional, Vilarrasa, E, additional, and Descalzo, MA, additional

Published
2024
Full Text
View/download PDF

16. Granulomas en dermatopatología: principales entidades. Parte I

Author

Aróstegui Aguilar, J., Diago, A., Carrillo Gijón, R., Fernández Figueras, M., Fraga, J., García Herrera, A., Garrido, M., Idoate Gastearena, M.Á., Christian Laga, Á., Llamas-Velasco, M., Martínez Campayo, N., Monteagudo, C., Onrubia, J., Pérez Muñoz, N., Ríos-Martín, J.J., Ríos-Viñuela, E., Rodríguez Peralto, J.L., Rozas Muñoz, E., Sanmartín, O., Santonja, C., Santos-Briz, Á., Saus, C., Suárez Peñaranda, J.M., Velasco Benito, V., Beato Merino, M.J., and Fernandez-Flores, A.

Published
2021
Full Text
View/download PDF

19. Dermatopatología de la oclusión intraluminal vascular: parte II (coagulopatías, émbolos y miscelánea)

Author

Beato Merino, M.J., Diago, A., Fernandez-Flores, A., Fraga, J., García Herrera, A., Garrido, M., Idoate Gastearena, M.A., Llamas-Velasco, M., Monteagudo, C., Onrubia, J., Pérez-González, Y.C., Pérez Muñoz, N., Ríos-Martín, J.J., Ríos-Viñuela, E., Rodríguez Peralto, J.L., Rozas Muñoz, E., Sanmartín, O., Santonja, C., Santos-Briz, A., Saus, C., Suárez Peñaranda, J.M., and Velasco Benito, V.

Published
2021
Full Text
View/download PDF

20. Dermatopatología de la oclusión intraluminal vascular: parte I (trombos)

Author

Beato Merino, M.J., Diago, A., Fernández-Flores, Á., Fraga, J., García Herrera, A., Garrido, M., Idoate Gastearena, M.Á., Llamas-Velasco, M., Monteagudo, C., Onrubia, J., Pérez-González, Y.C., Pérez Muñoz, N., Ríos-Martín, J.J., Ríos-Viñuela, E., Rodríguez Peralto, J.L., Rozas Muñoz, E., Sanmartín, O., Santonja, C., Santos-Briz, Á., Saus, C., Suárez Peñaranda, J.M., and Velasco Benito, V.

Published
2021
Full Text
View/download PDF

21. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study

Author

Torres, Tiago, Puig, Luis, Vender, Ron, Lynde, Charles, Piaserico, Stefano, Carrascosa, Jose M., Gisondi, Paolo, Daudén, Esteban, Conrad, Curdin, Mendes-Bastos, Pedro, Ferreira, Paulo, Leite, Luiz, Lu, Justin D., Valerio, J., Bruni, M., Messina, F., Nidegger, A., Llamas-Velasco, M., del Alcazar, E., Mufti, A., White, Kyra, Caldarola, G., Teixeira, Laetitia, Romanelli, Paolo, Desai, K., Gkalpakiotis, Spyridon, Romanelli, Marco, Yeung, Jensen, Nogueira, Miguel, and Chiricozzi, Andrea

Published
2021
Full Text
View/download PDF

22. Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real‐life clinical practice.

Author

Muñoz‐Aceituno, E., Butrón‐Bris, B., Ovejero‐Benito, M. C., Sahuquillo‐Torralba, A., Baniandrés Rodríguez, O., Herrera‐Acosta, E., Rivera‐Diaz, R., Ferran, M., Sánchez‐Carazo, J. L., Riera‐Monroig, J., Pujol‐Montcusí, J., Vidal, D., de la Cueva, P., García‐Bustinduy, M., Ruiz‐Villaverde, R., Ballescà, F., Llamas‐Velasco, M., Navares, M., Palomar‐Moreno, I., and Sánchez‐García, I.

Subjects
BIOTHERAPY, SENSITIVITY & specificity (Statistics), LOGISTIC regression analysis, TREATMENT effectiveness, REGRESSION analysis
Abstract

Background: Prediction of the response to a biological treatment in psoriasis patients would allow efficient treatment allocation. Objective: To identify polymorphisms associated with secukinumab response in psoriasis patients in a daily practice setting. Methods: We studied 180 SNPs in patients with moderate‐to‐severe plaque psoriasis recruited from 15 Spanish hospitals. Treatment effectiveness was evaluated by absolute PASI ≤3 and ≤1 at 6 and 12 months. Individuals were genotyped using a custom Taqman array. Multiple logistic regression models were generated. Sensitivity, specificity and area under the curve (AUC) were analysed. Results: A total of 173 patients were studied at 6 months, (67% achieved absolute PASI ≤ 3 and 65% PASI ≤ 1) and 162 at 12 months (75% achieved absolute PASI ≤ 3 and 64% PASI ≤ 1). Multivariable analysis showed the association of different sets of SNPs with the response to secukinumab. The model of absolute PASI≤3 at 6 months showed best values of sensitivity and specificity. Four SNPs were associated with the capability of achieving absolute PASI ≤ 3 at 6 months. rs1801274 (FCGR2A), rs2431697 (miR‐146a) and rs10484554 (HLCw6) were identified as risk factors for failure to achieve absolute PASI≤3, while rs1051738 (PDE4A) was protective. AUC including these genotypes, weight of patients and history of biological therapy was 0.88 (95% CI 0.83–0.94), with a sensitivity of 48.6% and specificity of 95.7% to discriminate between both phenotypes. Conclusion: We have identified a series of polymorphisms associated with the response to secukinumab capable of predicting the potential response/non‐response to this drug in patients with plaque psoriasis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Changing Trends in Drug Prescription and Causes of Treatment Discontinuation of First Biologic Over Ten Years in Psoriasis in the Spanish Biobadaderm Registry

Author

Ruiz-Genao, D.P., Carretero, G., Rivera, R., Ferrándiz, C., Daudén, E., de la Cuev, P., Belinchón, I., Gómez-García, F.J., Herrera-Acosta, E., López-Estebaranz, J.L., Ferrán-Farrés, M., Alsina, M., Baniandrés-Rodríguez, O., Sánchez-Carazo, J.L., Sahuquillo-Torralba, A., Rodriguez, L., Vilar-Alejo, J., García-Donoso, C., Carrascosa, J.M., Llamas-Velasco, M., Herrera-Ceballos, E., Botella-Estrada, R., Descalzo, M.A., and García-Doval, I.

Published
2020
Full Text
View/download PDF

24. Cambios en las tendencias de la prescripción y causas de la interrupción en los tratamientos biológicos indicados en la psoriasis durante los primeros 10 años. Datos obtenidos del registro español Biobadaderm

Author

Ruiz-Genao, D.P., Carretero, G., Rivera, R., Ferrándiz, C., Daudén, E., de la Cueva, P., Belinchón, I., Gómez-García, F.J., Herrera-Acosta, E., López-Estebaranz, J.L., Ferrán-Farrés, M., Alsina, M., Baniandrés-Rodríguez, O., Sánchez-Carazo, J.L., Sahuquillo-Torralba, A., Rodriguez, L., Vilar-Alejo, J., García-Donoso, C., Carrascosa, J.M., Llamas-Velasco, M., Herrera-Ceballos, E., Botella-Estrada, R., Descalzo, M.A., and García-Doval, I.

Published
2020
Full Text
View/download PDF

25. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

Author

Martorell, A., primary, Santos-Alarcón, S., additional, Sahuquillo-Torralba, A., additional, Rivera-Díaz, R., additional, Belinchón-Romero, I., additional, Ruiz-Genao, D., additional, Romero-Maté, A., additional, Ruiz-Villaverde, R., additional, Ferran-Farrés, M., additional, Gallardo-Hernández, F., additional, Almenara-Blasco, M., additional, Suarez-Perez, J.A., additional, González-Cantero, Á., additional, Martínez-Lorenzo, E., additional, Fernández-Armenteros, J.M., additional, del Alcázar-Viladomiu, E., additional, García-Latasa, J., additional, Rocamora-Durant, V., additional, Ara-Martín, M., additional, Mateu-Puchades, A., additional, Llamas-Velasco, M., additional, Vilarrasa, E., additional, Velasco-Pastor, M., additional, De la Cueva, P., additional, Carrascosa, J.M., additional, and Magdaleno-Tapial, J., additional

Published
2024
Full Text
View/download PDF

29. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real‐life clinical practice.

Author

Butrón‐Bris, B., Llamas‐Velasco, M., Ovejero‐Benito, M. C., Santos‐Juanes, J., Martínez‐López, A., Ruiz‐Villaverde, R., Roustan, G., Baniandrés, O., Izu‐Belloso, R., de la Cueva, P., Sahuquillo‐Torralba, A., Gónzalez‐Quesada, A., Vilarrasa‐Rull, E., Pujol‐Montcusí, J., García‐Martínez, J., Navares, M., Palomar‐Moreno, I., Novalbos, J., Abad‐Santos, F., and Daudén, E.

Subjects
*GENETIC polymorphisms, *GENETIC variation, *BIOTHERAPY, *DISEASE duration
Abstract

Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real‐life clinical practice. Ninety patients with plaque psoriasis recruited from—Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR <0.15 were included in a multiple regression model. Sixty three percent of patients achieved an absolute PASI ≤1 at 6 months, while 71% did so after 12 months. Disease duration (>27 years) and weight (>76 kg) were associated with treatment response; after correcting by these factors, no association (FDR >0.15) was found for any polymorphism and response to tildrakizumab at 6 months. The analysis at 12 months identified the genotype GG for rs610604 (TNFAIP3), CT for rs9373839 (ATG5), and delCTGT/delCTGT for rs72167053 (PDE4D) as risk factors to not achieve an optimal response (PASI ≤1), while CT for rs708567 (IL17RC) was protective, independently of weight and disease duration (FDR <0.15). The final multivariable model at 12 months showed an AUC of 0.90 (95% CI 0.82 to −0.98). We identified a set of polymorphisms that could be helpful to identify psoriatic patients with an optimal response to tildrakizumab at 12 months in real‐world practice conditions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Description of Patients Treated with Biologic Drugs as First-Line Systemic Therapy in the BIOBADADERM Registry Between 2008 and 2016

Author

Carretero Hernández, G., Ferrándiz, C., Rivera Díaz, R., Daudén Tello, E., de la Cueva-Dobao, P., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón Romero, I., López-Estebaranz, J.L., Alsina Gibert, M., Sánchez-Carazo, J.L., Ferrán Farrés, M., González Quesada, A., Carrascosa Carrillo, J.M., Llamas-Velasco, M., Mendiola Fernández, M.V., Ruiz Genao, D., Muñoz Santos, C., García-Doval, I., and Descalzo, M.A.

Published
2018
Full Text
View/download PDF

31. Descripción de los pacientes que reciben biológicos como primer tratamiento sistémico en el registro BIOBADADERM durante el periodo 2008-2016

Author

Carretero Hernández, G., Ferrándiz, C., Rivera Díaz, R., Daudén Tello, E., de la Cueva-Dobao, P., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón Romero, I., López-Estebaranz, J.L., Alsina Gibert, M., Sánchez-Carazo, J.L., Ferrán Farrés, M., González Quesada, A., Carrascosa Carrillo, J.M., Llamas-Velasco, M., Mendiola Fernández, M.V., Ruiz Genao, D., Muñoz Santos, C., García-Doval, I., and Descalzo, M.A.

Published
2018
Full Text
View/download PDF

32. [Translated article] Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study

Author

Jiménez Gómez, N., primary, González-Cantero, Á., additional, Ruiz-Villaverde, R., additional, Llamas-Velasco, M., additional, de la Cueva Dobao, P., additional, Rivera Díaz, R., additional, Martínez Lorenzo, E., additional, Alonso Pacheco, M.L., additional, Baniandrés Rodríguez, O., additional, Mollet Sánchez, J., additional, Pitarch Bort, G., additional, Izu Belloso, R.M., additional, and Jaén Olasolo, P., additional

Published
2023
Full Text
View/download PDF

39. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry

Author

Galiano Mejías, S., Carretero, G., Ferrandiz, C., Vanaclocha, F., Daudén, E., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón-Romero, I., Sánchez-Carazo, J.L., López-Estebaranz, J.L., Alsina, M., Ferrán, M., Torrado, R., Carrascosa, J.M., Rivera, R., Llamas-Velasco, M., Jiménez-Puya, R., Mendiola, Mª V., Ruiz-Genao, D., Descalzo, M.A., and de la Cueva Dobao, P.

Published
2017
Full Text
View/download PDF

40. Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm

Author

Galiano Mejías, S., Carretero, G., Ferrandiz, C., Vanaclocha, F., Daudén, E., Gómez-García, F.J., Herrera-Ceballos, E., Belinchón-Romero, I., Sánchez-Carazo, J.L., López-Estebaranz, J.L., Alsina, M., Ferrán, M., Torrado, R., Carrascosa, J.M., Rivera, R., Llamas-Velasco, M., Jiménez-Puya, R., Mendiola, Mª V., Ruiz-Genao, D., Descalzo, M.A., and de la Cueva Dobao, P.

Published
2017
Full Text
View/download PDF

43. Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population

Author

Sahuquillo‐Torralba, A., primary, Hospital‐Gil, M., additional, Vilarrasa‐Rull, E., additional, Llamas‐Velasco, M., additional, Rivera, R., additional, Carrascosa, J. M., additional, de la Cueva‐Dovao, P., additional, Armesto‐Santos, S., additional, Ruíz‐Villaverde, R., additional, Velasco‐Pastor, M., additional, Magdaleno‐Tapial, J., additional, Yanguas‐Bayona, J. I., additional, Ribera‐Pibernat, M., additional, Salgado‐Boquete, L., additional, Herranz‐Pinto, P., additional, Romero‐Mate, A., additional, Martínez‐Lorenzo, E., additional, López‐Estebaranz, J. L., additional, Ballescá‐López, F., additional, and Botella‐Estrada, R., additional

Published
2023
Full Text
View/download PDF

44. Percepción de la mujer con psoriasis en la planificación familiar: Estudio descriptivo, transversal y multicéntrico

Author

Jiménez Gómez, N., primary, González-Cantero, Á., additional, Ruiz-Villaverde, R., additional, Llamas-Velasco, M., additional, de la Cueva Dobao, P., additional, Rivera Díaz, R., additional, Martínez Lorenzo, E., additional, Alonso Pacheco, M.L., additional, Baniandrés Rodríguez, O., additional, Mollet Sánchez, J., additional, Pitarch Bort, G., additional, Izu Belloso, R.M., additional, and Jaén Olasolo, P., additional

Published
2023
Full Text
View/download PDF

46. Metachronous primary secretory carcinomas of the eyelid and the parotid gland.

Author

Llamas‐Velasco, M., Kiss, K., Melchior, L., and Mentzel, T.

Subjects
*PAROTID glands, *EYELIDS, *CHROMOSOMAL translocation, *CARCINOMA, *CANCER relapse, *SURGICAL excision
Abstract

This article, published in the Journal of Cutaneous Pathology, discusses a case of metachronous primary secretory carcinomas (SC) in the eyelid and parotid gland. SCs are rare tumors that are mainly found in the parotid gland, but can also occur in other locations such as the eyelid. Histopathologically, SCs are characterized by secretions within the cells and a specific chromosomal translocation. The article presents the case of a patient who had two separate SCs in the eyelid and parotid gland, and discusses the differential diagnosis and prognosis of these tumors. The patient did not experience recurrence or metastasis after surgical excision of both tumors. [Extracted from the article]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results